(19)
(11) EP 4 247 392 A1

(12)

(43) Date of publication:
27.09.2023 Bulletin 2023/39

(21) Application number: 20939425.3

(22) Date of filing: 03.06.2020
(51) International Patent Classification (IPC): 
A61K 31/7115(2006.01)
A61K 31/125(2006.01)
 A61K 31/712(2006.01)
C12N 15/113(2010.01)
(52) Cooperative Patent Classification (CPC):
C12N 15/113; A61K 31/712; A61K 31/7115; A61K 31/7125; C12N 2310/11; C12N 2310/315; C12N 2310/3341; C12N 2310/3231
 
C-Sets:
C12N 2310/321, C12N 2310/3525;
(86) International application number:
PCT/US2020/035972
(87) International publication number:
WO 2021/247020 (09.12.2021 Gazette 2021/49)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(71) Applicant: Takeda Pharmaceuticals U.S.A., Inc.
Lexington, MA 02421 (US)

(72) Inventors:
  • BERMINGHAM, Nessan Anthony
    Cambridge, Massachusetts 02139 (US)
  • BETTENCOURT, Brian R.
    Cambridge, Massachusetts 02139 (US)
  • GE, Pei
    Cambridge, MA 02139 (US)

(74) Representative: Pohlman, Sandra M. 
df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte PartG mbB Theatinerstrasse 16
80333 München
80333 München (DE)

   


(54) METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY